olaparib
merck,astrazeneca
['propel']
updated safety results from propel olap: tt aes - within first 4 months; recovery in first 6 months (except fatigue) anemia: most common ae with olap + abi; 34% dose interruption, 23% dose , 8% treatment discont pe: olap + abi 6.5% vs abi 1.8%, #asco22 
Uro Onc @GACancerCenter | Res PD & Ronald W. Lewis MD Chair of Uro Educ @mcg_urology | Digital Media Ed @EUplatinum | #mentalhealth research | @urotoday